CRO FlowMetric gets into diagnostics with new spinout

Pennsylvania CRO FlowMetric is zeroing in on companion diagnostics, launching a new company to put its platform technology to use in developing tests.

FlowMetric is a niche CRO that provides cell counting and sorting services to drug developers, technology that comes in handy when validating targets, affirming safety and running clinical trials.

Now the company is looking to expand its platform, forming the affiliate FlowMetric Diagnostics to develop and market assays based on its in-house technology.

The plan is to establish a state-of-the-art, FDA-compliant lab and perform CLIA-certified diagnostic tests for clients, the company said, making use of the flow cytometry technology that helped build its client base.

"The development of new companion diagnostics through flow cytometry can help to advance personalized medicine and better meet the needs of physicians, healthcare workers and patients," FlowMetric Diagnostics President Amy Williams said in a statement.

- read the statement

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.